1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NIH Exploratory/Developmental Grant (R21) is sponsored by National Cancer Institute (NCI). This grant mechanism supports exploratory and developmental research projects, often involving considerable risk but with the potential to generate highly innovative findings in pancreatic cancer research.
While an older, expired R21 (PA-08-208) specifically mentioned pancreatic cancer, the current R21 parent announcement allows for a wide range of innovative research. Projects focusing on novel approaches to understand and overcome resistance to KRAS inhibitors and EGFR combinations in pancreatic cancer would be suitable.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Universities, colleges, hospitals, non-profits, for-profit organizations, state and local governments, and other institutions. This mechanism is ideal for pilot projects in early and conceptual stages. Confirm the full requirements in the official notice before applying.
The current listing shows direct costs limited to $275,000 over a two-year period, with no more than $200,000 in direct costs allowed in any single year. Verify award ceilings, matching requirements, and allowable costs in the official notice.
NIH Exploratory/Developmental Grant (R21) is funded by National Cancer Institute (NCI). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
On May 21, 2026, the National Cancer Institute posted RFA-CA-27-006, RFA-CA-27-007, and RFA-CA-27-008 — the three competitive renewals for the NCI Community Oncology Research Program. Combined FY 2027 commitments reach $147.5 million across roughly 57 awards: $74.5 million for up to 7 Research Bases, $73 million for up to 50 Community and Academic Community Sites. Pre-application webinars run June 16-18 this week. Applications are due August 18, 2026 with six-year project periods. For community hospitals, oncology consortia, and NCI-designated cancer centers, this is the single largest cancer clinical-trials infrastructure decision NCI makes until 2033.
Read articleThe Breast Cancer Research Foundation launched a $100 million venture philanthropy fund at CGI on September 22, 2026, seeded with $23 million and aiming at 20 to 30 companies. Here is what the structure actually means for investigators, for startups in the valley of death, and for every disease foundation now weighing the same move.
Read articlePAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read article